Table 3.
Comparison of the clinical and pathological characteristics between the two groups before and after the matching procedure.
| MBC patients (n = 40) | FBC patients before PSM (n = 2678) | p-valuea | FBC patients after PSM (n = 120) | p-valueb | |
|---|---|---|---|---|---|
| Age (years) | |||||
| Median (min–max) | 73 (54–94) | 66 (24–100) | p = 0.001 | 77 (46–95) | p = 0.30 |
| Year of surgery | |||||
| 2004–2006 | 9 (22.50%) | 395 (14.75%) | p = 0.07 | 25 (20.93%) | p = 0.73 |
| 2007–2009 | 5 (12.5%) | 397 (14.83%) | 21 (17.50%) | ||
| 2010–2012 | 8 (20.00%) | 512 (19.12%) | 19 (15.83%) | ||
| 2013–2015 | 4 (10.00%) | 538 (20.09%) | 20 (16.67%) | ||
| 2016–2019 | 14 (35.00%) | 836 (31.22%) | 35 (29.17%) | ||
| Type of surgery | |||||
| Conservative | 0 (0.00%) | 1791 (66.88%) | p < 0.001 | 0 (0.00%) | p = 1.00 |
| Mastectomy | 40 (100.00%) | 887 (33.12%) | 120 (100.00%) | ||
| Tumor stage | |||||
| In situ | 3 (7.50%) | 272 (10.16%) | p = 0.001 | 6 (5.00%) | p = 0.85 |
| T1a–b | 2 (5.00%) | 653 (24.38%) | 10 (8.33%) | ||
| T1c | 16 (40.00%) | 946 (35.32%) | 41 (34.17%) | ||
| T2 | 14 (35.0%) | 645 (24.09%) | 49 (40.83%) | ||
| T3–T4 | 5 (12.50%) | 79 (2.95%) | 14 (11.67%) | ||
| 83 (3.10%) | |||||
| Nodal stage | |||||
| N0 | 18 (45.00%) | 1799 (67.18%) | p = 0.001 | 49 (40.83%) | p = 0.96 |
| N1mi | 1 (2.50%) | 443 (16.54%) | 50 (41.67%) | ||
| N1a–b | 16 (40.00%) | 171 (6.39%) | 3 (2.50%) | ||
| N2–N3 | 5 (12.50%) | 265 (9.90%) | 18 (15.0%) | ||
| Grading | |||||
| G1 | 6 (15.00%) | 304 (11.35%) | p = 0.67 | 8 (6.67%) | p = 0.20 |
| G2 | 22 (55.00%) | 1556 (58.10%) | 86 (71.67%) | ||
| G3 | 11 (27.50%) | 649 (24.23%) | 23 (19.17%) | ||
| GX | 1 (2.50%) | 169 (6.41%) | 3 (2.50%) | ||
| Ki-67 | |||||
| < 20 | 15 (37.50%) | 1587 (59.26%) | p = 0.006 | 65 (54.17%) | p = 0.07 |
| ≥ 20 | 25 (62.50%) | 1091 (40.74%) | 55 (46.83%) | ||
| Molecular profile | |||||
| In situ | 3 (7.50%) | 276 (10.31%) | p = 0.03 | 6 (5.00%) | p = 0.91 |
| Luminal A | 15 (37.50%) | 1121 (41.86%) | 51 (42.50%) | ||
| Luminal B HER2- | 16 (40.00%) | 800 (29.87%) | 46 (38.33%) | ||
| Luminal B HER2+ | 6 (15.00%) | 155 (5.79%) | 17 (14.17%) | ||
| HER2+ | 0 (0.00%) | 87 (3.35%) | 0 (0.00%) | ||
| Triple negative | 0 (0.00%) | 239 (8.92%) | 0 (0.00%) | ||
| Cancer recurrence | |||||
| Yes | 6 (15%) | 203 (7.58%) | p = 0.07 | 8 (6.67%) | p = 0.10 |
| No | 34 (85%) | 2474 (92.42%) | 112 (93.33%) | ||
| Death | |||||
| Yes | 12 (30%) | 444 (16.59%) | p = 0.02 | 43 (35.83%) | p = 0.02 |
| No | 28 (70%) | 2233 (83.41%) | 77 (64.17%) | ||
MBC male breast cancer, FBC female breast cancer, PSM propensity score matching.
ap-value results before matching procedure.
bp-value results after matching procedure.